Show simple item record

dc.contributor.authorYoumans, Katherine L.
dc.contributor.authorTai, Leon M.
dc.contributor.authorNwabuisi-Heath, Evelyn
dc.contributor.authorJungbauer, Lisa
dc.contributor.authorKanekiyo, Takahisa
dc.contributor.authorGan, Ming
dc.contributor.authorKim, Jungsu
dc.contributor.authorEimer, William A.
dc.contributor.authorEstus, Steve
dc.contributor.authorRebeck, G. William
dc.contributor.authorWeeber, Edwin J
dc.contributor.authorBu, Guojun
dc.contributor.authorYu, Chunjiang
dc.contributor.authorLaDu, Mary Jo
dc.date.accessioned2013-11-26T21:19:56Z
dc.date.available2013-12-06T18:47:33Z
dc.date.issued2012-12
dc.identifier.bibliographicCitationYoumans, K. L. Tai, L. M. Nwabuisi-Heath, E. Jungbauer, L. Kanekiyo, T. Gan, M. Kim, J. Eimer, W. A. Estus, S. Rebeck, G. W. Weeber, E. J. Bu, G. J. Yu, C. J. LaDu, M. J.. APOE4-specific Changes in A beta Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry. Dec 2012;287(50):41774-41786. DOI: 10.1074/jbc.M112.407957en_US
dc.identifier.issn0021-9258
dc.identifier.urihttp://hdl.handle.net/10027/10672
dc.descriptionThis research was originally published in APOE4-specific Changes in A beta Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Youmans, K. L. Tai, L. M. Nwabuisi-Heath, E. Jungbauer, L. Kanekiyo, T. Gan, M. Kim, J. Eimer, W. A. Estus, S. Rebeck, G. W. Weeber, E. J. Bu, G. J. Yu, C. J. LaDu, M. J. Journal of Biological Chemistry. Dec 2012;287(50):41774-41786. © the American Society for Biochemistry and Molecular Biologyen_US
dc.description.abstractAPOE4 is the greatest risk factor for Alzheimer disease (AD) and synergistic effects with amyloid-beta peptide (A beta) suggest interactions among apoE isoforms and different forms of A beta accumulation. However, it remains unclear how the APOE genotype affects plaque morphology, intraneuronal A beta, soluble A beta 42, and oligomeric A beta (oA beta), particularly in vivo. As the introduction of human APOE significantly delays amyloid deposition in transgenic mice expressing familial AD (FAD) mutations (FAD-Tg), 5xFAD-Tg mice, which exhibit amyloid deposition by age 2 months, were crossed with apoE-targeted replacement mice to produce the new EFAD-Tg mice. Compared with 5xFAD mice, A beta deposition was delayed by similar to 4 months in the EFAD mice, allowing detection of early changes in A beta accumulation from 2-6 months. Although plaque deposition is generally greater in E4FAD mice, E2/E3FAD mice have significantly more diffuse and E4FAD more compact plaques. As a first report in FAD-Tg mice, the APOE genotypes had no effect on intraneuronal A beta accumulation in EFAD mice. In E4FAD mice, total apoE levels were lower and total A beta levels higher than in E2FAD and E3FAD mice. Profiles from sequential three-step extractions (TBS, detergent, and formic acid) demonstrated that the lower level of total apoE4 is reflected only in the detergent-soluble fraction, indicating that less apoE4 is lipoprotein-associated, and perhaps less lipidated, compared with apoE2 and apoE3. Soluble A beta 42 and oA beta levels were highest in E4FAD mice, although soluble apoE2, apoE3, and apoE4 levels were comparable, suggesting that the differences in soluble A beta 42 and oA beta result from functional differences among the apoE isoforms. Thus, APOE differentially regulates multiple aspects of A beta accumulation.en_US
dc.language.isoen_USen_US
dc.publisherAmerican Society for Biochemistry and Molecular Biologyen_US
dc.subjectAPOE genotypeen_US
dc.subjectAD transgenic mouse modelen_US
dc.titleAPOE4-specific Changes in A beta Accumulation in a New Transgenic Mouse Model of Alzheimer Diseaseen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record